EDIT — Editas Medicine, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1650664 ·
Last close
$2.84
Market Cap
$436.17M
52W High
$4.33
52W Low
$1.66
ADV30
2,973,379
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 11,890,000 | — | -19,893,000 | -18,230,000 | 237,364,000 | 181,815,000 | 132,083,000 |
| Mar 2026 | 2,831,000 | — | -25,003,000 | -24,982,000 | 149,338,000 | 123,648,000 | 144,930,000 |
| Dec 2025 | 24,741,000 | — | -14,016,000 | -5,620,000 | 186,534,000 | 146,645,000 | 159,246,000 |
| Sep 2025 | 7,543,000 | — | -24,548,000 | -25,117,000 | 201,751,000 | 165,648,000 | 188,298,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-119,859,000
Investing CF
$9,895,000
Financing CF
$152,030,000
CapEx
$-691,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.75
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,671,715,000
Inventory
—
Receivables
$2,725,000
ST Investments
$29,830,000
EBIT TTM
$-69,881,000
Pretax Income TTM
$-73,949,000
Interest Exp TTM
$4,068,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$47,005,000
EBITDA
$-81,035,000
Free Cash Flow
$-44,316,000
Enterprise Value
$218,532,096
Total Cash
$211,644,992
Total Debt
$15,511,000
Shares Out
153,580,035
Trailing EPS
$-0.66
Book Value
$0.69
ROE
-118.8%
ROA
-23.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 40,520,000 | -99,336,000 | -160,060,000 | 186,534,000 | 159,246,000 | 27,288,000 | -165,241,000 |
| Dec 2024 | 32,314,000 | -238,920,000 | -237,093,000 | 341,589,000 | 207,315,000 | 134,274,000 | -210,284,000 |
| Dec 2023 | 78,123,000 | -169,181,000 | -153,219,000 | 499,153,000 | 150,056,000 | 349,097,000 | -132,178,000 |
| Dec 2022 | 19,712,000 | -225,950,000 | -220,432,000 | 514,321,000 | 153,641,000 | 360,680,000 | -177,349,000 |
TTM Snapshot
Revenues TTM
$38,693,000
NetIncome TTM
$-108,954,000
OpCashFlow TTM
—
Assets (Latest)
$149,338,000
Forward EPS
$-0.75
Max Pain — expiry 2027-01-15
max pain strike: $2.50 · spot: $2.80 · call oi: 10,565 · put oi: 732
Expected Move to 2027-01-15:
±$1.12
(40.25%) —
implied range
$1.67 –
$3.92
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ENTX | Entera Bio Ltd. | $432.85M | $2.50 | — |
| TECX | Tectonic Therapeutic, Inc. | $444.75M | $22.75 | — |
| AGMB | AgomAb Therapeutics NV | $454.07M | $9.22 | — |
| EIKN | Eikon Therapeutics, Inc. | $406.24M | $7.50 | — |
| AUTL | Autolus Therapeutics plc | $471.11M | $1.77 | — |
News headlines (Yahoo Finance, 1h cache)
Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027
2026-10-08 17:25 · Yahoo
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
2026-09-12 01:01 · Yahoo
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
2026-09-09 13:00 · Yahoo
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
2026-09-08 11:00 · Yahoo
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
2026-09-04 15:30 · Yahoo
Editas Medicine to Participate in Upcoming Investor Conferences
2026-09-01 13:00 · Yahoo
Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates
2026-08-05 22:10 · Yahoo
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
2026-08-05 20:01 · Yahoo
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
2026-08-04 20:15 · Yahoo
Sector Update: Healthcare Stocks Softer Late Afternoon
2026-10-08 19:53 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.